Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702. Issue 1 (July 2015)

• Record Type: Journal Article
• Authors: Inoue, Akira; Sugawara, Shunichi; Maemondo, Makoto; Mori, Yoshiaki; Oizumi, Satoshi; Harada, Masao; Taima, Kageaki; Morikawa, Naoto; Ishida, Takashi; Kinoshita, Ichiro; Watanabe, Hiroshi; Suzuki, Toshiro; Nakagawa, Taku; Saito, Ryota; Nukiwa, Toshihiro
• Is Part Of: Lung cancer. Volume 89:Issue 1(2015:Jul.)
• Page Start: 61
• Page End: 65
• Publication Date: 2015-07
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.04.012
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">This randomized phase II was conducted to select a proper regimen for phase III.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Amrubicin achieved a higher ORR and a longer PFS than re-challenge of platinum.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Only amrubicin met the primary endpoint, which deserves further investigation.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Toxicity was generally acceptable and no treatment-related death was observed.</p> </list-item> </list> </p> </sec> </abstract>